Symbols / PLSE Stock $27.23 +13.63% Pulse Biosciences, Inc.
PLSE (Stock) Chart
Stock Fundamentals
|
|
|
|
|
|
About
Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers nPulse System, a novel Nanosecond Pulsed-Field Ablation delivery platform to treat benign lesions of the skin; nPulse Vybrance Percutaneous Electrode system for soft tissue ablation in surgical setting; nPulse Cardiac Surgical Clamp designed for use in surgical treatment of atrial fibrillation (AF); nPulse Cardiac Catheter System designed to provide a circumferential, or circular, ablation in a single treatment cycle; and nPulse Console, a software-enabled console-based platform designed to accommodate the clinical workflow preferred by physicians. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Miami, Florida.
Ratings
Current target
$27.23
Low
$30.00
High
$30.00
Mean
$30.00
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-07-07 | init | Oppenheimer | — → Outperform | $22 |
| 2022-09-21 | down | Maxim Group | Buy → Hold | — |
| 2022-05-13 | down | HC Wainwright & Co. | Buy → Neutral | — |
| 2022-04-01 | main | Stephens & Co. | — → Overweight | $12 |
| 2022-04-01 | main | HC Wainwright & Co. | — → Buy | $9 |
| 2022-02-10 | main | HC Wainwright & Co. | — → Buy | $20 |
| 2021-11-16 | main | HC Wainwright & Co. | — → Buy | $43 |
| 2021-07-27 | init | Stephens & Co. | — → Overweight | $28 |
| 2021-03-11 | init | Maxim Group | — → Buy | $40 |
| 2021-01-26 | main | HC Wainwright & Co. | — → Buy | $40 |
| 2020-05-12 | up | HC Wainwright & Co. | Neutral → Buy | $16 |
| 2020-02-14 | down | HC Wainwright & Co. | Buy → Neutral | $6 |
| 2019-02-25 | init | HC Wainwright & Co. | — → Buy | — |
- Pulse Biosciences (NASDAQ: PLSE) Q1 2026 results, cash burn and AF strategy - Stock Titan hu, 14 May 2026 13
- Pulse Biosciences (PLSE) Stock Soars After Insider Buying - GuruFocus ue, 12 May 2026 22
- Pulse Biosciences (PLSE) Stock Jumps 17% After $13M Insider Buy - CoinCentral ue, 12 May 2026 14
- Pulse Biosciences (PLSE) Stock Surges 17% on Major $13M Insider Purchase - MEXC ue, 12 May 2026 18
- Pulse Biosciences stock jumps after insiders buy $13.3M in shares - Investing.com Nigeria ue, 12 May 2026 14
- PLUS Stock Price, Quote & Chart | EPLUS INC (NASDAQ:PLUS) - ChartMill Mon, 11 May 2026 07
- ATM Equity Purchases by Pulse Biosciences’ Co-Chairmen Total Approximately $13.3 Million - Yahoo Finance ue, 12 May 2026 11
- [SCHEDULE 13D/A] PULSE BIOSCIENCES, INC. Amended Major Shareholder Report - Stock Titan Wed, 13 May 2026 22
- Pulse Biosciences (PLSE) Co-Chairmen Invest $13.3M in Company St - GuruFocus Wed, 13 May 2026 03
- Pulse Biosciences stock jumps after insiders buy $13.3M in shares - Investing.com ue, 12 May 2026 14
- Pulse Biosciences (NASDAQ: PLSE) CEO adds 15,000 shares in open-market buy - Stock Titan ue, 12 May 2026 00
- Robert Duggan adds 660K Pulse Biosciences (PLSE) shares in open-market buy - Stock Titan Mon, 11 May 2026 22
- Pulse Biosciences director Robert Duggan buys $13 million in shares By Investing.com - Investing.com Nigeria Mon, 11 May 2026 23
- [Form 4] PULSE BIOSCIENCES, INC. Insider Trading Activity - Stock Titan Mon, 11 May 2026 22
- Pulse Biosciences CEO Paul Laviolette buys $295,350 in company stock By Investing.com - Investing.com Nigeria Mon, 11 May 2026 23
Insider Transactions
Financials
Statement View
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
0.35
|
0.00
|
0.00
-100.00%
|
0.70
|
| Operating Revenue |
|
0.35
|
0.00
|
0.00
-100.00%
|
0.70
|
| Cost Of Revenue |
|
0.54
|
0.00
|
0.00
-100.00%
|
11.94
|
| Reconciled Cost Of Revenue |
|
0.54
|
0.00
|
0.00
-100.00%
|
11.94
|
| Gross Profit |
|
-0.19
|
0.00
|
0.00
+100.00%
|
-11.24
|
| Operating Expense |
|
76.75
+36.43%
|
56.26
+29.11%
|
43.57
-6.92%
|
46.81
|
| Research And Development |
|
44.72
+38.30%
|
32.34
+16.33%
|
27.80
+33.39%
|
20.84
|
| Selling General And Administration |
|
32.03
+33.89%
|
23.92
+51.62%
|
15.78
-39.26%
|
25.97
|
| Selling And Marketing Expense |
|
—
|
—
|
0.00
-100.00%
|
12.02
|
| General And Administrative Expense |
|
—
|
23.92
+51.62%
|
15.78
+13.06%
|
13.96
|
| Other Gand A |
|
—
|
23.92
+51.62%
|
15.78
+13.06%
|
13.96
|
| Total Expenses |
|
77.29
+37.39%
|
56.26
+29.11%
|
43.57
-25.84%
|
58.76
|
| Operating Income |
|
-76.94
-36.76%
|
-56.26
-29.11%
|
-43.57
+24.95%
|
-58.06
|
| Total Operating Income As Reported |
|
-76.94
-36.76%
|
-56.26
-29.11%
|
-43.57
+24.95%
|
-58.06
|
| EBITDA |
|
-75.87
-37.74%
|
-55.08
-30.00%
|
-42.37
+25.28%
|
-56.70
|
| Normalized EBITDA |
|
-75.87
-37.74%
|
-55.08
-30.00%
|
-42.37
+25.28%
|
-56.70
|
| Reconciled Depreciation |
|
1.07
-9.08%
|
1.18
-2.40%
|
1.21
-10.92%
|
1.35
|
| EBIT |
|
-76.94
-36.76%
|
-56.26
-29.11%
|
-43.57
+24.95%
|
-58.06
|
| Net Income |
|
-72.78
-35.82%
|
-53.59
-26.95%
|
-42.21
+27.85%
|
-58.51
|
| Pretax Income |
|
-72.78
-35.82%
|
-53.59
-26.95%
|
-42.21
+27.85%
|
-58.51
|
| Net Non Operating Interest Income Expense |
|
4.21
+56.51%
|
2.69
+97.21%
|
1.36
+404.46%
|
-0.45
|
| Net Interest Income |
|
4.21
+56.51%
|
2.69
+97.21%
|
1.36
+404.46%
|
-0.45
|
| Interest Income Non Operating |
|
4.21
+56.51%
|
2.69
|
—
|
—
|
| Interest Income |
|
4.21
+56.51%
|
2.69
|
—
|
—
|
| Other Income Expense |
|
-0.05
-188.89%
|
-0.02
|
—
|
—
|
| Other Non Operating Income Expenses |
|
-0.05
-188.89%
|
-0.02
|
—
|
—
|
| Tax Provision |
|
—
|
0.00
|
0.00
|
0.00
|
| Tax Rate For Calcs |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-72.78
-35.82%
|
-53.59
-26.95%
|
-42.21
+27.85%
|
-58.51
|
| Net Income From Continuing Operation Net Minority Interest |
|
-72.78
-35.82%
|
-53.59
-26.95%
|
-42.21
+27.85%
|
-58.51
|
| Net Income From Continuing And Discontinued Operation |
|
-72.78
-35.82%
|
-53.59
-26.95%
|
-42.21
+27.85%
|
-58.51
|
| Net Income Continuous Operations |
|
-72.78
-35.82%
|
-53.59
-26.95%
|
-42.21
+27.85%
|
-58.51
|
| Normalized Income |
|
-72.78
-35.82%
|
-53.59
-26.95%
|
-42.21
+27.85%
|
-58.51
|
| Net Income Common Stockholders |
|
-72.78
-35.82%
|
-53.59
-26.95%
|
-42.21
+27.85%
|
-58.51
|
| Diluted EPS |
|
—
|
-0.92
-8.24%
|
-0.85
+49.74%
|
-1.69
|
| Basic EPS |
|
—
|
-0.92
-8.24%
|
-0.85
+49.74%
|
-1.69
|
| Basic Average Shares |
|
—
|
58.40
+17.41%
|
49.74
+44.12%
|
34.51
|
| Diluted Average Shares |
|
—
|
58.40
+17.41%
|
49.74
+44.12%
|
34.51
|
| Diluted NI Availto Com Stockholders |
|
-72.78
-35.82%
|
-53.59
-26.95%
|
-42.21
+27.85%
|
-58.51
|
| Total Other Finance Cost |
|
—
|
-2.67
-95.89%
|
-1.36
-404.46%
|
0.45
|
| Line Item | Trend | 2023-12-31 |
|---|---|---|
| Total Assets |
|
59.15
|
| Current Assets |
|
45.33
|
| Cash Cash Equivalents And Short Term Investments |
|
44.37
|
| Cash And Cash Equivalents |
|
44.37
|
| Other Short Term Investments |
|
—
|
| Receivables |
|
—
|
| Accounts Receivable |
|
—
|
| Inventory |
|
—
|
| Raw Materials |
|
—
|
| Work In Process |
|
—
|
| Finished Goods |
|
—
|
| Prepaid Assets |
|
—
|
| Other Current Assets |
|
0.96
|
| Total Non Current Assets |
|
13.83
|
| Net PPE |
|
8.78
|
| Gross PPE |
|
12.26
|
| Accumulated Depreciation |
|
-3.48
|
| Properties |
|
0.00
|
| Machinery Furniture Equipment |
|
1.24
|
| Construction In Progress |
|
0.00
|
| Other Properties |
|
8.50
|
| Leases |
|
2.52
|
| Goodwill And Other Intangible Assets |
|
4.68
|
| Goodwill |
|
2.79
|
| Other Intangible Assets |
|
1.89
|
| Other Non Current Assets |
|
0.36
|
| Total Liabilities Net Minority Interest |
|
14.79
|
| Current Liabilities |
|
6.71
|
| Payables And Accrued Expenses |
|
2.45
|
| Payables |
|
1.84
|
| Accounts Payable |
|
1.84
|
| Current Accrued Expenses |
|
0.61
|
| Pensionand Other Post Retirement Benefit Plans Current |
|
3.20
|
| Current Debt And Capital Lease Obligation |
|
1.06
|
| Current Debt |
|
—
|
| Other Current Borrowings |
|
—
|
| Current Capital Lease Obligation |
|
1.06
|
| Current Deferred Liabilities |
|
—
|
| Current Deferred Revenue |
|
—
|
| Total Non Current Liabilities Net Minority Interest |
|
8.09
|
| Long Term Debt And Capital Lease Obligation |
|
8.09
|
| Long Term Debt |
|
—
|
| Long Term Capital Lease Obligation |
|
8.09
|
| Stockholders Equity |
|
44.36
|
| Common Stock Equity |
|
44.36
|
| Capital Stock |
|
0.06
|
| Common Stock |
|
0.06
|
| Preferred Stock |
|
0.00
|
| Share Issued |
|
56.08
|
| Ordinary Shares Number |
|
56.08
|
| Treasury Shares Number |
|
0.00
|
| Additional Paid In Capital |
|
381.22
|
| Retained Earnings |
|
-336.92
|
| Gains Losses Not Affecting Retained Earnings |
|
0.00
|
| Total Equity Gross Minority Interest |
|
44.36
|
| Total Capitalization |
|
44.36
|
| Working Capital |
|
38.62
|
| Invested Capital |
|
44.36
|
| Total Debt |
|
9.14
|
| Net Debt |
|
—
|
| Capital Lease Obligations |
|
9.14
|
| Net Tangible Assets |
|
39.68
|
| Tangible Book Value |
|
39.68
|
| Current Notes Payable |
|
—
|
| Current Provisions |
|
—
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-54.12
-48.92%
|
-36.34
-9.99%
|
-33.04
+29.72%
|
-47.01
|
| Cash Flow From Continuing Operating Activities |
|
-54.12
-48.92%
|
-36.34
-9.99%
|
-33.04
+29.72%
|
-47.01
|
| Net Income From Continuing Operations |
|
-72.78
-35.82%
|
-53.59
-26.95%
|
-42.21
+27.85%
|
-58.51
|
| Depreciation Amortization Depletion |
|
1.07
-9.08%
|
1.18
-2.40%
|
1.21
-10.92%
|
1.35
|
| Depreciation |
|
0.41
-20.70%
|
0.51
-5.54%
|
0.54
-21.45%
|
0.69
|
| Amortization Cash Flow |
|
0.67
-0.15%
|
0.67
+0.15%
|
0.67
+0.00%
|
0.67
|
| Depreciation And Amortization |
|
1.07
-9.08%
|
1.18
-2.40%
|
1.21
-10.92%
|
1.35
|
| Amortization Of Intangibles |
|
0.67
-0.15%
|
0.67
+0.15%
|
0.67
+0.00%
|
0.67
|
| Other Non Cash Items |
|
1.15
+24.92%
|
0.92
|
—
|
—
|
| Stock Based Compensation |
|
21.46
+57.93%
|
13.59
+89.19%
|
7.18
+38.34%
|
5.19
|
| Asset Impairment Charge |
|
—
|
—
|
0.00
-100.00%
|
8.48
|
| Operating Gains Losses |
|
—
|
0.01
-53.85%
|
0.01
-92.97%
|
0.18
|
| Gain Loss On Sale Of PPE |
|
0.00
-100.00%
|
0.01
-53.85%
|
0.01
-92.97%
|
0.18
|
| Change In Working Capital |
|
-5.02
-424.21%
|
1.55
+101.69%
|
0.77
+120.67%
|
-3.72
|
| Change In Receivables |
|
-0.27
|
0.00
-100.00%
|
0.11
+445.00%
|
0.02
|
| Changes In Account Receivables |
|
-0.27
|
0.00
|
0.00
-100.00%
|
0.06
|
| Change In Inventory |
|
-0.14
|
0.00
|
0.00
+100.00%
|
-2.65
|
| Change In Prepaid Assets |
|
-0.91
-156.90%
|
-0.35
-446.15%
|
-0.07
-105.58%
|
1.16
|
| Change In Payables And Accrued Expense |
|
-2.32
-176.98%
|
3.01
+269.90%
|
0.81
+137.34%
|
-2.18
|
| Change In Accrued Expense |
|
-3.45
-207.41%
|
3.21
+482.94%
|
0.55
+162.90%
|
-0.88
|
| Change In Payable |
|
1.13
+663.18%
|
-0.20
-176.43%
|
0.26
+120.17%
|
-1.30
|
| Change In Account Payable |
|
1.13
+663.18%
|
-0.20
-176.43%
|
0.26
+120.17%
|
-1.30
|
| Change In Other Working Capital |
|
—
|
—
|
—
|
-0.02
|
| Change In Other Current Assets |
|
-0.01
+54.84%
|
-0.03
-103.85%
|
0.81
+11.48%
|
0.72
|
| Change In Other Current Liabilities |
|
-1.37
-27.14%
|
-1.08
-20.09%
|
-0.90
-15.76%
|
-0.77
|
| Investing Cash Flow |
|
-0.34
-168.00%
|
-0.12
-3.31%
|
-0.12
+69.83%
|
-0.40
|
| Cash Flow From Continuing Investing Activities |
|
-0.34
-168.00%
|
-0.12
-3.31%
|
-0.12
+69.83%
|
-0.40
|
| Net PPE Purchase And Sale |
|
-0.32
-152.00%
|
-0.12
-3.31%
|
-0.12
+69.83%
|
-0.40
|
| Purchase Of PPE |
|
-0.32
-152.00%
|
-0.12
-3.31%
|
-0.12
+69.83%
|
-0.40
|
| Capital Expenditure |
|
-0.34
-168.00%
|
-0.12
-3.31%
|
-0.12
+69.83%
|
-0.40
|
| Net Investment Purchase And Sale |
|
—
|
—
|
—
|
0.00
|
| Purchase Of Investment |
|
—
|
—
|
—
|
0.00
|
| Sale Of Investment |
|
—
|
—
|
—
|
0.00
|
| Net Intangibles Purchase And Sale |
|
-0.02
|
0.00
|
—
|
—
|
| Purchase Of Intangibles |
|
-0.02
|
0.00
|
—
|
—
|
| Financing Cash Flow |
|
17.15
-84.43%
|
110.14
+572.08%
|
16.39
-79.50%
|
79.94
|
| Cash Flow From Continuing Financing Activities |
|
17.15
-84.43%
|
110.14
+572.08%
|
16.39
-79.50%
|
79.94
|
| Net Issuance Payments Of Debt |
|
—
|
—
|
0.00
-100.00%
|
65.00
|
| Issuance Of Debt |
|
—
|
—
|
0.00
-100.00%
|
65.00
|
| Repayment Of Debt |
|
—
|
—
|
—
|
-0.44
|
| Long Term Debt Issuance |
|
—
|
—
|
0.00
-100.00%
|
65.00
|
| Long Term Debt Payments |
|
—
|
—
|
—
|
—
|
| Net Long Term Debt Issuance |
|
—
|
—
|
0.00
-100.00%
|
65.00
|
| Short Term Debt Issuance |
|
—
|
—
|
—
|
65.00
|
| Short Term Debt Payments |
|
—
|
—
|
—
|
-0.44
|
| Net Short Term Debt Issuance |
|
—
|
—
|
—
|
64.56
|
| Net Common Stock Issuance |
|
0.00
-100.00%
|
59.65
|
0.00
-100.00%
|
14.86
|
| Proceeds From Stock Option Exercised |
|
17.15
-66.21%
|
50.77
+209.70%
|
16.39
+3101.95%
|
0.51
|
| Net Other Financing Charges |
|
—
|
-0.28
-4583.33%
|
-0.01
+98.63%
|
-0.44
|
| Changes In Cash |
|
-37.30
-150.63%
|
73.67
+539.21%
|
-16.77
-151.57%
|
32.52
|
| Beginning Cash Position |
|
118.04
+166.06%
|
44.37
-27.44%
|
61.14
+113.67%
|
28.61
|
| End Cash Position |
|
80.73
-31.60%
|
118.04
+166.06%
|
44.37
-27.44%
|
61.14
|
| Free Cash Flow |
|
-54.46
-49.33%
|
-36.47
-9.97%
|
-33.16
+30.06%
|
-47.41
|
| Amortization Of Securities |
|
—
|
—
|
—
|
0.00
|
| Change In Interest Payable |
|
—
|
0.00
+100.00%
|
-0.67
-172.77%
|
0.92
|
| Common Stock Issuance |
|
0.00
-100.00%
|
59.65
|
0.00
-100.00%
|
14.86
|
| Issuance Of Capital Stock |
|
0.00
-100.00%
|
59.65
|
0.00
-100.00%
|
14.86
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 10-Q2026-05-14 View
- 42026-05-11 View
- 42026-05-11 View
- 8-K2026-05-06 View
- 8-K2026-05-04 View
- 8-K2026-04-27 View
- 8-K2026-04-16 View
- 8-K2026-04-09 View
- 8-K2026-04-07 View
- 42026-04-03 View
- 8-K2026-03-27 View
- 8-K2026-03-17 View
- 8-K2026-03-12 View
- 8-K2026-03-09 View
- 8-K2026-03-03 View
- 8-K2026-02-27 View
- 42026-02-23 View
- 8-K2026-02-19 View
- 8-K2026-02-19 View
- 10-K2026-02-19 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|